Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 10/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179666 | 0.95 | VDR (0.48) | VDRHDAC3HDAC2HDAC6 | |
| SCHEMBL26326335 | 0.95 | VDR (0.48) | VDRHDAC3HDAC2HDAC6 | |
| SCHEMBL8063708 | 0.95 | VDR (0.48) | VDRHDAC3HDAC2HDAC6 | |
| SCHEMBL26756751 | 0.90 | VDR (0.50) | VDRHDAC3HDAC2HDAC6 | |
| SCHEMBL12398156 | 0.89 | VDR (0.48) | VDR | |
| SCHEMBL12398191 | 0.88 | VDR (0.47) | VDR | |
| SCHEMBL13531894 | 0.87 | VDR (0.45) | VDR | |
| SCHEMBL12398139 | 0.87 | VDR (0.53) | VDR | |
| SCHEMBL12397972 | 0.86 | VDR (0.50) | VDR | |
| SCHEMBL13531897 | 0.86 | VDR (0.55) | VDRHDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | TEIJIN PHARMA LIMITED (JP) | 2023-11-02 | — | — | US | disclosed |
| US-9212136-B2 | Methods for producing paricalcitol | AZAD PHARMACEUTICALS INGREDIENTS AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20110184199-A1 | Methods For Producing Paricalcitol | AZAD PHARMA AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | MCGILL UNIVERSITY (CA) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | VDR, HDAC3, HDAC4 | VDR 1/4885HDAC3 2/4885HDAC2 10/4885 |
| US-20230348376-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | VDR, CYP2R1, CYP24A1 | VDR 1/4885HDAC3 371/4885HDAC2 891/4885 |
| US-20110184199-A1 | Methods For Producing Paricalcitol | CYP2R1, PTH1R, CYP24A1 | VDR 18/4885HDAC3 4207/4885HDAC2 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.